Crucially, this absorption pathway displays non-linear kinetics, meaning that it can become easily saturated
The observation that the insulinotropic actions of GLP-1 are reduced in type 2 diabetes mellitus (T2DM) led to the development of incretin-based therapies GLP-1 receptor agonists and dipeptidyl peptidase 4 (DPP-4) inhibitors for the treatment of hyperglycaemia in these patients
Why this matters: Daily oral semaglutide offers an alternative to weekly injections Lower cash prices compared to injectables: $149$299/month Available at 70,000+ pharmacies (CVS, Costco) and telehealth platforms like Ro, LifeMD, Weight Watchers, GoodRx, and NovoCare Approved not only for weight loss, but also for reducing cardiovascular risk in adults with obesity Clinical impact: Phase 3 trials showed up to 16.6% average weight loss at 64 weeks Same active ingredient as injectable Wegovy, targeting appetite via GLP-1 pathways Industry perspective: With the global GLP-1 market projected to approach $100B by the 2030s, oral therapies may capture nearly 24% of the market, reshaping access, adherence, and affordability
As use of GLP-1 receptor agonists continues to expand, the integration of conventional clinical evidence with large-scale observational data may offer a more complete picture of how these therapies affect patients in routine practice
[DOI] [PubMed] [Google Scholar] 37.Narcisi P, Richards AJ, Ferguson SD, Pope FM
Retrieved from FDA Approved Drugs
